In-vivo Transmission Model in Semi-immune Adults

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 9, 2024

Primary Completion Date

February 13, 2024

Study Completion Date

June 30, 2024

Conditions
Controlled Human Malaria InfectionInduced Blood Stage Malaria InfectionMalaria TransmissionMalaria Challenge
Interventions
DRUG

Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg).

The first arm will receive Piperaquine tablets, that will be administered orally. Sub-curative regimen will be given as two tablets of 320mg and 160mg (total of 480mg).

DRUG

Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.

The second arm will receive Doxycycline (100mg tablets strength as Doxycycline hyclate) that will also be administered orally. Sub-curative regimen will be given as 1 tablet (100mg) once daily for 7 days.

Trial Locations (1)

Unknown

Ifakara Health Institute, Pwani

All Listed Sponsors
collaborator

University of Oxford

OTHER

lead

Ifakara Health Institute

OTHER